Royal (Royal.io) is a US-based music rights marketplace that lets fans buy ownership stakes in songs and earn streaming royalties alongside artists. Founded in May 2021 by DJ and producer Justin '3LAU' Blau and Opendoor co-founder JD Ross, the platform sells Limited Digital Assets (LDAs) - blockchain-based tokens that grant buyers a share of a song's streaming royalty rights plus associated benefits. Artists including Nas, Diplo, and The Chainsmokers have sold royalty rights through the platform.
Royal is publicly traded
IPO'd on June 16, 2020
This company is no longer available on our private secondary market. Shares can be traded publicly under RPRX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2021
Employees
80–100
Total Funding
$71M
1 rounds
Total raised $71M across 1 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-02-2026
Latest Round
Type
Private placement
Date
1996
Amount
$60M
Valuation
—
Lead Investors
Justin Blau
Co-Founder & CEO
JD Ross
Co-Founder
Competitor list is illustrative and may be incomplete, stale, or erroneous.
HealthCare Royalty Partners
Stamford-based royalty acquisition and synthetic royalty financing firm focused on commercial-stage biopharmaceutical assets.
RTW Investments
Healthcare-focused investment firm that provides royalty and structured financing to biopharma companies alongside its public and private equity strategies.
XOMA Royalty
Nasdaq-listed biotech royalty aggregator that acquires potential future royalties and milestones on early- and mid-stage clinical assets.
Sagard Healthcare Partners
Healthcare credit and royalty investing platform within Sagard, providing structured debt and royalty capital to biopharma issuers.
Ligand Pharmaceuticals
Royalty-aggregator biopharma firm whose business model centers on acquiring and licensing royalty streams and economic rights to partnered programs.
Yes, Royal is publicly traded under the ticker symbol RPRX on the Nasdaq. The company went public in June 16, 2020.
Royal trades under the ticker symbol RPRX on the Nasdaq. It began trading in June 16, 2020.
Royal (RPRX on the Nasdaq) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker RPRX to place an order.
Royal went public in June 16, 2020 via ipo. Royalty Pharma priced its IPO on June 15, 2020 and began trading on the Nasdaq Global Select Market under ticker RPRX on June 16, 2020 at $28.00 per Class A ordinary share. The deal closed June 18, 2020 with 89,333,920 shares (including the full greenshoe), raising approximately $2.5 billion in gross proceeds, the largest healthcare IPO at the time. Shares opened at $44 on debut, valuing the company at roughly $26 billion. The company trades on Nasdaq as RPRX.
Royal raised $71M across 1 disclosed funding rounds prior to its public listing.
Royal was co-founded by Justin Blau, and JD Ross in 2021.
Royal is headquartered in Austin, Texas, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.